Stay updated on Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial page.

Latest updates to the Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision label updated to v3.4.2 and the prior funding-status notice was removed; these are site-wide maintenance updates that do not affect study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding lapse notice with links to cc.nih.gov and opm.gov for status updates. Updated the page revision stamp to v3.4.1, replacing the prior v3.4.0.SummaryDifference0.4%

- Check28 days agoChange DetectedGlossary visibility has been added to the page. Metadata lines were updated to show 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0' (replacing the previous 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4').SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3 on the page; no changes to study details or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedThe Locations section now includes a New York site, replacing the previous 'New York Locations' label. The page revision shows v3.3.3 and the HHS Vulnerability Disclosure link has been removed.SummaryDifference0.2%

- Check85 days agoChange DetectedFooter revision label updated from v3.3.1 to v3.3.2; no user-facing content or functionality appears affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib-Nivolumab Combo in Hematologic Malignancies Clinical Trial page.